The Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, 240 East 38th Street, 12th Floor, New York, NY, 10016, USA.
University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Arch Dermatol Res. 2024 Aug 12;316(8):510. doi: 10.1007/s00403-024-03261-0.
Low dose oral minoxidil (LDOM) is an efficacious and safe treatment for alopecia, however, a notable side effect is hypertrichosis. Spironolactone, known for treating hirsutism, is also used off-label for the treatment of certain forms of alopecia and may reduce LDOM-induced hypertrichosis. We performed a retrospective review of 54 patients seen at NYU Langone Health and compared hypertrichosis rates in female alopecia patients on LDOM monotherapy versus those on combination therapy with spironolactone. Among 54 patients, 37 received LDOM alone and 17 received the combination. Hypertrichosis developed in 33.3% of patients, with lower rates in the combination group (17.6% vs. 40.5% for monotherapy). Although not statistically significant, the trend suggests spironolactone may mitigate hypertrichosis. The study highlights the potential of combination therapy to address hypertrichosis and calls for larger studies to confirm these findings.
低剂量口服米诺地尔（LDOM）是治疗脱发的有效且安全的方法，但一个显著的副作用是多毛症。螺内酯是一种用于治疗多毛症的药物，也被超适应证用于治疗某些类型的脱发，并且可能会减轻 LDOM 引起的多毛症。我们对在纽约大学朗格尼健康中心就诊的 54 名患者进行了回顾性研究，并比较了 LDOM 单药治疗的女性脱发患者和螺内酯联合治疗的患者的多毛症发生率。在 54 名患者中，37 名患者接受 LDOM 单药治疗，17 名患者接受联合治疗。多毛症在 33.3%的患者中发生，联合治疗组的发生率较低（单药治疗组为 40.5%，联合治疗组为 17.6%）。虽然没有统计学意义，但这一趋势表明螺内酯可能减轻多毛症。该研究强调了联合治疗在解决多毛症方面的潜力，并呼吁进行更大规模的研究来证实这些发现。
